Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Идиопатический рецидивирующий перикардит: вчера, сегодня, завтра - Журнал Терапевтический архив №12 Vario 2025
Идиопатический рецидивирующий перикардит: вчера, сегодня, завтра
Сафиуллина А.А., Петрухина А.А., Осмоловская Ю.Ф., Жиров И.В., Терещенко С.Н. Идиопатический рецидивирующий перикардит: вчера, сегодня, завтра. Терапевтический архив. 2025;97(12):965–972. DOI: 10.26442/00403660.2025.12.203447
© ООО «КОНСИЛИУМ МЕДИКУМ», 2025 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2025 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Идиопатический рецидивирующий перикардит (ИРП) – это орфанное воспалительное заболевание перикарда, характеризующееся отсутствием патогномоничных симптомов и специфичных биомаркеров. Постановка диагноза осложняется отсутствием как характерных клинических признаков, так и специфических маркеров рецидива ИРП, что затрудняет своевременное назначение патогенетической терапии и значимо ухудшает прогноз. Для решения проблем, связанных со сложной дифференциальной диагностикой, низкой настороженностью врачей и отсутствием унифицированных методических рекомендаций по ИРП для врачей общей практики, терапевтов и кардиологов, возникла необходимость в создании специализированного экспертного центра. Этот центр призван обеспечить синергию высококвалифицированных врачей различных специальностей для точного подтверждения диагноза.
Ключевые слова: идиопатический рецидивирующий перикардит, экспертный центр идиопатического рецидивирующего перикардита, орфанное заболевание, аутовоспаление, инфламмасома, интерлейкин-1
Keywords: idiopathic recurrent pericarditis, expert center for idiopathic recurrent pericarditis, orphan disease, autoinflammation, inflammasome, interleukin-1
Ключевые слова: идиопатический рецидивирующий перикардит, экспертный центр идиопатического рецидивирующего перикардита, орфанное заболевание, аутовоспаление, инфламмасома, интерлейкин-1
________________________________________________
Keywords: idiopathic recurrent pericarditis, expert center for idiopathic recurrent pericarditis, orphan disease, autoinflammation, inflammasome, interleukin-1
Полный текст
Список литературы
1. Schulz-Menger J, Collini V, Gröschel J, et al.; the ESC Scientific Document Group. 2025 ESC Guidelines for the management of myocarditis and pericarditis: Developed by the task force for the management of myocarditis and pericarditis of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2025;46(40):3952-4041. DOI:10.1093/eurheartj/ehaf192
2. Skajaa N, Horváth-Puhó E, Adelborg K, et al. Lack of seasonality in occurrence of pericarditis, myocarditis, and endocarditis. Ann Epidemiol. 2019;37:77-80. DOI:10.1016/j.annepidem.2019.07.005
3. Chiabrando JG, Bonaventura A, Vecchié A, et al. Management of acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(1):76-92. DOI:10.1016/j.jacc.2019.11.021
4. Мячикова В.Ю., Маслянский А.Л., Моисеева О.М. Идиопатический рецидивирующий перикардит – новое орфанное аутовоспалительное заболевание? Ретроспективный анализ случаев идиопатического рецидивирующего перикардита и план рандомизированного, плацебо-контролируемого исследования для оценки терапевтической эффективности и безопасности блокатора ИЛ-1 (RPH-104). Кардиология. 2021;61(1):72-7 [Myachikova VYu, Maslyanskiy AL, Moiseeva OM. Idiopathic recurrent pericarditis – a new orphan autoinflammatory disease? A retrospective analysis of cases of idiopathic recurrent pericarditis and a design of а double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of RPH-104 treatment in patients with idiopathic recurrent pericarditis. Kardiologiia. 2021;61(1):72-7 (in Russian)]. DOI:10.18087/cardio.2021.1.n1475
5. Перечень редких (орфанных) заболеваний. 2025. Режим доступа: https://minzdrav.gov.ru/documents/9641-perechen-redkih-orfannyh-zabolevaniy. Ссылка активна на 05.06.2025 [Perechen' redkikh (orfannykh) zabolevanii. 2025. Available at: https://minzdrav.gov.ru/documents/9641-perechen-redkih-orfannyh-zabolevaniy. Accessed: 05.06.2025 (in Russian)].
6. Arlie R, Barnes MD, Howard B, Burchell MD. Acute pericarditis simulating acute coronary occlusion: A report of fourteen cases. Am Heart J. 1942;23(2):247-68. DOI:10.1016/S0002-8703(42)90383-1
7. Wolff L. Acute pericarditis simulating myocardial infarction. New Engl J Med. 1944;230:422-5.
8. Bourne WA. Acute pericarditis simulating myocardial infarction. Br Med J. 1949;2(4627):579. DOI:10.1136/bmj.2.4627.579
9. Peel AAF. Diseases of the heart and circulation. London, New York: Geoffrey Cumberlege, Oxford University Press, 1947.
10. Cross EG, Charles WB. Idiopathic pericarditis. Can Med Assoc J. 1953;68(3):237-43. PMID:13032863
11. Dressler W. A post-myocardial infarction syndrome; preliminary report of a complication resembling idiopathic, recurrent, benign pericarditis. J Am Med Assoc. 1956;160(16):1379-83. DOI:10.1001/jama.1956.02960510005002
12. Bell JF, Meis A. Pericarditis in infection due to Coxsackie virus group B, type 3. N Engl J Med. 1959;261(3):126-8. DOI:10.1056/NEJM195907162610304
13. Agranat AL. A near-fatal case of Coxsackie B1 myocarditis (with pericarditis) in an adult. S Afr Med J. 1961;35:831-3. PMID:13859634
14. Smith WG. Adult heart disease due to the Coxsackie virus group B. Br Heart J. 1966;28(2):204-20. DOI:10.1136/hrt.28.2.204
15. McDermott M, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97(1):133-44. DOI:10.1016/s0092-8674(00)80721-7
16. Bonaventura A, Vecchié A, Mauro AG, et al. An update on the pathophysiology of acute and recurrent pericarditis. Panminerva Med. 2021;63(3):249-60. DOI:10.23736/S0031-0808.20.04205-6
17. Yang X, Lin G, Han Z, Chai J. Structural Biology of NOD-Like Receptors. Adv Exp Med Biol. 2019;1172:119-41. DOI:10.1007/978-981-13-9367-9_6
18. Sundaram B, Kanneganti TD. Advances in understanding activation and function of the NLRC4 inflammasome. Int J Mol Sci. 2021;22(3):1048. DOI:10.3390/ijms22031048
19. Jiang L, Shao Y, Tian Y, et al. Nuclear alarmin cytokines in inflammation. J Immunol Res. 2020;2020:7206451. DOI:10.1155/2020/7206451
20. Vong CT, Tseng HHL, Yao P, et al. Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases. Drug Discov Today. 2021;26(6):1394-408. DOI:10.1016/j.drudis.2021.02.018
21. Tombetti E, Casarin F, Bizzi E, et al. Relapsing pericarditis: peripheral blood neutrophilia, lymphopenia and high neutrophilto-lymphocyte ratio herald acute attacks, high-grade inflammation, multiserosal involvement, and predict multiple recurrences. Int J Rheum Dis. 2023;26(2):337-43. DOI:10.1111/175 6-185X.14523
22. Imazio M, Brucato A, Maestroni S, et al. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: Implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation. 2011;123(10):1092-7. DOI:10.1161/CIRCULATIONAHA.110.986372
23. Перикардиты. Клинические рекомендации РКО 2025. Режим доступа: https://scardio.ru/content/Guidelines/KR_Perikardity.pdf. Ссылка активна на 10.11.2025 [Perikardity. Klinicheskie rekomendatsii RKO 2025. Available at: https://scardio.ru/content/Guidelines/KR_Perikardity.pdf. Accessed: 10.11.2025 (in Russian)].
24. Klein AL, Wang TKM, Cremer PC, et al. Pericardial diseases: International position statement on new concepts and advances in multimodality cardiac imaging. JACC Cardiovasc Imaging. 2024;17:937-88. DOI:10.1016/j.jcmg.2024.04.010
25. Wang TKM, Ayoub K, Chetrit M, et al. Cardiac magnetic resonance imaging techniques and their application in pericardial diseases. Circ Cardiovasc Imaging. 2022;15:e014283. DOI:10.1161/CIRCIMAGING.122.014283
26. Klein AL, Abbara S, Agler DA, et al. American Society of Echocardiography clinical practice guidelines for multimodality cardiovascular imaging in patients with pericardial disease: Endorsed by the Society of Cardiovascular Magnetic Resonance Imaging and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2013;26(9):965-1012.e15. DOI:10.1016/j.echo.2013.06.023
27. Wang TKM, Klein AL, Cremer PC, et al. 2025 Concise Clinical Guidance: An ACC Expert Consensus statement on the diagnosis and management of pericarditis: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2025;86(25):2691-719. DOI:10.1016/j.jacc.2025.05.023
28. Horneffer PJ, Miller RH, Pearson TA, et al. The effective treatment of ostpericardiotomy syndrome after cardiac operations. A randomized placebo-controlled trial. J Thorac Cardiovasc Surg. 1990;100:292-6. PMID:2200931
29. Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160(14):2093-9. DOI:10.1001/archinte.160.14.2093
30. Lamberts M, Lip GY, Hansen ML, et al. Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: A nationwide cohort study. Ann Intern Med. 2014;161(10):690-8. DOI:10.7326/M13-1581
31. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153(4):477-84. PMID:8435027
32. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S-24S. DOI:10.1016/s0002-9343(99)00113-8
33. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: A meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3(4):231-41. DOI:10.1016/S2468-1253(18)30037-2
34. Rodríguez de la Serna A, Guindo Soldevila J, Martí Claramunt V, Bayés de Luna A. Colchicine for recurrent pericarditis. Lancet. 1987;2(8574):1517. DOI:10.1016/s0140-6736(87)92641-9
35. Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. 2021;42(28):2745-60. DOI:10.1093/eurheartj/ehab221
36. Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute Pericarditis: results of the Colchicine for acute Pericarditis (COPE) trial. Circulation. 2005;112(13):2012-6. DOI:10.1161/CIRCULATIONAHA.105.542738
37. Imazio M, Brucato A, Cemin R, et al.; ICAP investigators. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522-8. DOI:10.1056/NEJMoa1208536
38. Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent Pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155(7):409-14. DOI:10.7326/0003-4819-155-7-201110040-00360
39. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of Colchicine for treatment of multiple recurrences of Pericarditis (CORP-2): A multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383(9936):2232-7. DOI:10.1016/S0140-6736(13)62709-9
40. Imazio M, Brucato A, Cumetti D, et al. Corticosteroids for recurrent pericarditis: high versus low doses: A nonrandomized observation. Circulation. 2008;118(6):667-71. DOI:10.1161/CIRCULATIONAHA.107.761064
41. Lazaros G, Antonopoulos AS, Vlachopoulos C, et al. Predictors of switching from nonsteroidal anti-inflammatory drugs to corticosteroids in patients with acute pericarditis and impact on clinical outcome. Hellenic J Cardiol. 2019;60(6):357-63. DOI:10.1016/j.hjc.2018.04.001
42. Imazio M, Lazaros G. Corticosteroids for pericarditis: A warning but don’t throw the baby out with the bathwater. Hellenic J Cardiol. 2019;60(6):364-5. DOI:10.1016/j.hjc.2019.04.002
43. Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis in patients with colchicine resistance and corticosteroid dependence: The AIRTRIP randomized clinical trial. JAMA. 2016;316(18):1906-12. DOI:10.1001/jama.2016.15826
44. Klein AL, Imazio M, Brucato A, et al. RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis. Am Heart J. 2020;228:81-90. DOI:10.1016/j.ahj.2020.07.004
45. Myachikova VY, Maslyanskiy AL, Moiseeva OM, et al. Treatment of idiopathic recurrent pericarditis with goflikicept: Phase II/III study results. J Am Coll Cardiol. 2023;82(1):30-40. DOI:10.1016/j.jacc.2023.04.046
46. Imazio M, Brucato A, Mayosi BM, et al. Medical therapy of pericardial diseases: Part II: Noninfectious pericarditis, pericardial effusion and constrictive pericarditis. J Cardiovasc Med (Hagerstown). 2010;11(11):785-94. PMID: 20925146.
47. Imazio M, Brucato A, Maestroni S, et al. Risk of constrictive pericarditis after acute pericarditis. Circulation. 2011;124(11):1270-5. DOI:10.1161/CIRCULATIONAHA.111.018580
2. Skajaa N, Horváth-Puhó E, Adelborg K, et al. Lack of seasonality in occurrence of pericarditis, myocarditis, and endocarditis. Ann Epidemiol. 2019;37:77-80. DOI:10.1016/j.annepidem.2019.07.005
3. Chiabrando JG, Bonaventura A, Vecchié A, et al. Management of acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(1):76-92. DOI:10.1016/j.jacc.2019.11.021
4. Myachikova VYu, Maslyanskiy AL, Moiseeva OM. Idiopathic recurrent pericarditis – a new orphan autoinflammatory disease? A retrospective analysis of cases of idiopathic recurrent pericarditis and a design of а double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of RPH-104 treatment in patients with idiopathic recurrent pericarditis. Kardiologiia. 2021;61(1):72-7 (in Russian). DOI:10.18087/cardio.2021.1.n1475
5. Perechen' redkikh (orfannykh) zabolevanii. 2025. Available at: https://minzdrav.gov.ru/documents/9641-perechen-redkih-orfannyh-zabolevaniy. Accessed: 05.06.2025 (in Russian).
6. Arlie R, Barnes MD, Howard B, Burchell MD. Acute pericarditis simulating acute coronary occlusion: A report of fourteen cases. Am Heart J. 1942;23(2):247-68. DOI:10.1016/S0002-8703(42)90383-1
7. Wolff L. Acute pericarditis simulating myocardial infarction. New Engl J Med. 1944;230:422-5.
8. Bourne WA. Acute pericarditis simulating myocardial infarction. Br Med J. 1949;2(4627):579. DOI:10.1136/bmj.2.4627.579
9. Peel AAF. Diseases of the heart and circulation. London, New York: Geoffrey Cumberlege, Oxford University Press, 1947.
10. Cross EG, Charles WB. Idiopathic pericarditis. Can Med Assoc J. 1953;68(3):237-43. PMID:13032863
11. Dressler W. A post-myocardial infarction syndrome; preliminary report of a complication resembling idiopathic, recurrent, benign pericarditis. J Am Med Assoc. 1956;160(16):1379-83. DOI:10.1001/jama.1956.02960510005002
12. Bell JF, Meis A. Pericarditis in infection due to Coxsackie virus group B, type 3. N Engl J Med. 1959;261(3):126-8. DOI:10.1056/NEJM195907162610304
13. Agranat AL. A near-fatal case of Coxsackie B1 myocarditis (with pericarditis) in an adult. S Afr Med J. 1961;35:831-3. PMID:13859634
14. Smith WG. Adult heart disease due to the Coxsackie virus group B. Br Heart J. 1966;28(2):204-20. DOI:10.1136/hrt.28.2.204
15. McDermott M, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97(1):133-44. DOI:10.1016/s0092-8674(00)80721-7
16. Bonaventura A, Vecchié A, Mauro AG, et al. An update on the pathophysiology of acute and recurrent pericarditis. Panminerva Med. 2021;63(3):249-60. DOI:10.23736/S0031-0808.20.04205-6
17. Yang X, Lin G, Han Z, Chai J. Structural Biology of NOD-Like Receptors. Adv Exp Med Biol. 2019;1172:119-41. DOI:10.1007/978-981-13-9367-9_6
18. Sundaram B, Kanneganti TD. Advances in understanding activation and function of the NLRC4 inflammasome. Int J Mol Sci. 2021;22(3):1048. DOI:10.3390/ijms22031048
19. Jiang L, Shao Y, Tian Y, et al. Nuclear alarmin cytokines in inflammation. J Immunol Res. 2020;2020:7206451. DOI:10.1155/2020/7206451
20. Vong CT, Tseng HHL, Yao P, et al. Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases. Drug Discov Today. 2021;26(6):1394-408. DOI:10.1016/j.drudis.2021.02.018
21. Tombetti E, Casarin F, Bizzi E, et al. Relapsing pericarditis: peripheral blood neutrophilia, lymphopenia and high neutrophilto-lymphocyte ratio herald acute attacks, high-grade inflammation, multiserosal involvement, and predict multiple recurrences. Int J Rheum Dis. 2023;26(2):337-43. DOI:10.1111/175 6-185X.14523
22. Imazio M, Brucato A, Maestroni S, et al. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: Implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation. 2011;123(10):1092-7. DOI:10.1161/CIRCULATIONAHA.110.986372
23. Perikardity. Klinicheskie rekomendatsii RKO 2025. Available at: https://scardio.ru/content/Guidelines/KR_Perikardity.pdf. Accessed: 10.11.2025 (in Russian).
24. Klein AL, Wang TKM, Cremer PC, et al. Pericardial diseases: International position statement on new concepts and advances in multimodality cardiac imaging. JACC Cardiovasc Imaging. 2024;17:937-88. DOI:10.1016/j.jcmg.2024.04.010
25. Wang TKM, Ayoub K, Chetrit M, et al. Cardiac magnetic resonance imaging techniques and their application in pericardial diseases. Circ Cardiovasc Imaging. 2022;15:e014283. DOI:10.1161/CIRCIMAGING.122.014283
26. Klein AL, Abbara S, Agler DA, et al. American Society of Echocardiography clinical practice guidelines for multimodality cardiovascular imaging in patients with pericardial disease: Endorsed by the Society of Cardiovascular Magnetic Resonance Imaging and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2013;26(9):965-1012.e15. DOI:10.1016/j.echo.2013.06.023
27. Wang TKM, Klein AL, Cremer PC, et al. 2025 Concise Clinical Guidance: An ACC Expert Consensus statement on the diagnosis and management of pericarditis: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2025;86(25):2691-719. DOI:10.1016/j.jacc.2025.05.023
28. Horneffer PJ, Miller RH, Pearson TA, et al. The effective treatment of ostpericardiotomy syndrome after cardiac operations. A randomized placebo-controlled trial. J Thorac Cardiovasc Surg. 1990;100:292-6. PMID:2200931
29. Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160(14):2093-9. DOI:10.1001/archinte.160.14.2093
30. Lamberts M, Lip GY, Hansen ML, et al. Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: A nationwide cohort study. Ann Intern Med. 2014;161(10):690-8. DOI:10.7326/M13-1581
31. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153(4):477-84. PMID:8435027
32. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S-24S. DOI:10.1016/s0002-9343(99)00113-8
33. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: A meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3(4):231-41. DOI:10.1016/S2468-1253(18)30037-2
34. Rodríguez de la Serna A, Guindo Soldevila J, Martí Claramunt V, Bayés de Luna A. Colchicine for recurrent pericarditis. Lancet. 1987;2(8574):1517. DOI:10.1016/s0140-6736(87)92641-9
35. Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. 2021;42(28):2745-60. DOI:10.1093/eurheartj/ehab221
36. Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute Pericarditis: results of the Colchicine for acute Pericarditis (COPE) trial. Circulation. 2005;112(13):2012-6. DOI:10.1161/CIRCULATIONAHA.105.542738
37. Imazio M, Brucato A, Cemin R, et al.; ICAP investigators. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522-8. DOI:10.1056/NEJMoa1208536
38. Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent Pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155(7):409-14. DOI:10.7326/0003-4819-155-7-201110040-00360
39. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of Colchicine for treatment of multiple recurrences of Pericarditis (CORP-2): A multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383(9936):2232-7. DOI:10.1016/S0140-6736(13)62709-9
40. Imazio M, Brucato A, Cumetti D, et al. Corticosteroids for recurrent pericarditis: high versus low doses: A nonrandomized observation. Circulation. 2008;118(6):667-71. DOI:10.1161/CIRCULATIONAHA.107.761064
41. Lazaros G, Antonopoulos AS, Vlachopoulos C, et al. Predictors of switching from nonsteroidal anti-inflammatory drugs to corticosteroids in patients with acute pericarditis and impact on clinical outcome. Hellenic J Cardiol. 2019;60(6):357-63. DOI:10.1016/j.hjc.2018.04.001
42. Imazio M, Lazaros G. Corticosteroids for pericarditis: A warning but don’t throw the baby out with the bathwater. Hellenic J Cardiol. 2019;60(6):364-5. DOI:10.1016/j.hjc.2019.04.002
43. Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis in patients with colchicine resistance and corticosteroid dependence: The AIRTRIP randomized clinical trial. JAMA. 2016;316(18):1906-12. DOI:10.1001/jama.2016.15826
44. Klein AL, Imazio M, Brucato A, et al. RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis. Am Heart J. 2020;228:81-90. DOI:10.1016/j.ahj.2020.07.004
45. Myachikova VY, Maslyanskiy AL, Moiseeva OM, et al. Treatment of idiopathic recurrent pericarditis with goflikicept: Phase II/III study results. J Am Coll Cardiol. 2023;82(1):30-40. DOI:10.1016/j.jacc.2023.04.046
46. Imazio M, Brucato A, Mayosi BM, et al. Medical therapy of pericardial diseases: Part II: Noninfectious pericarditis, pericardial effusion and constrictive pericarditis. J Cardiovasc Med (Hagerstown). 2010;11(11):785-94. PMID: 20925146.
47. Imazio M, Brucato A, Maestroni S, et al. Risk of constrictive pericarditis after acute pericarditis. Circulation. 2011;124(11):1270-5. DOI:10.1161/CIRCULATIONAHA.111.018580
2. Skajaa N, Horváth-Puhó E, Adelborg K, et al. Lack of seasonality in occurrence of pericarditis, myocarditis, and endocarditis. Ann Epidemiol. 2019;37:77-80. DOI:10.1016/j.annepidem.2019.07.005
3. Chiabrando JG, Bonaventura A, Vecchié A, et al. Management of acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(1):76-92. DOI:10.1016/j.jacc.2019.11.021
4. Мячикова В.Ю., Маслянский А.Л., Моисеева О.М. Идиопатический рецидивирующий перикардит – новое орфанное аутовоспалительное заболевание? Ретроспективный анализ случаев идиопатического рецидивирующего перикардита и план рандомизированного, плацебо-контролируемого исследования для оценки терапевтической эффективности и безопасности блокатора ИЛ-1 (RPH-104). Кардиология. 2021;61(1):72-7 [Myachikova VYu, Maslyanskiy AL, Moiseeva OM. Idiopathic recurrent pericarditis – a new orphan autoinflammatory disease? A retrospective analysis of cases of idiopathic recurrent pericarditis and a design of а double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of RPH-104 treatment in patients with idiopathic recurrent pericarditis. Kardiologiia. 2021;61(1):72-7 (in Russian)]. DOI:10.18087/cardio.2021.1.n1475
5. Перечень редких (орфанных) заболеваний. 2025. Режим доступа: https://minzdrav.gov.ru/documents/9641-perechen-redkih-orfannyh-zabolevaniy. Ссылка активна на 05.06.2025 [Perechen' redkikh (orfannykh) zabolevanii. 2025. Available at: https://minzdrav.gov.ru/documents/9641-perechen-redkih-orfannyh-zabolevaniy. Accessed: 05.06.2025 (in Russian)].
6. Arlie R, Barnes MD, Howard B, Burchell MD. Acute pericarditis simulating acute coronary occlusion: A report of fourteen cases. Am Heart J. 1942;23(2):247-68. DOI:10.1016/S0002-8703(42)90383-1
7. Wolff L. Acute pericarditis simulating myocardial infarction. New Engl J Med. 1944;230:422-5.
8. Bourne WA. Acute pericarditis simulating myocardial infarction. Br Med J. 1949;2(4627):579. DOI:10.1136/bmj.2.4627.579
9. Peel AAF. Diseases of the heart and circulation. London, New York: Geoffrey Cumberlege, Oxford University Press, 1947.
10. Cross EG, Charles WB. Idiopathic pericarditis. Can Med Assoc J. 1953;68(3):237-43. PMID:13032863
11. Dressler W. A post-myocardial infarction syndrome; preliminary report of a complication resembling idiopathic, recurrent, benign pericarditis. J Am Med Assoc. 1956;160(16):1379-83. DOI:10.1001/jama.1956.02960510005002
12. Bell JF, Meis A. Pericarditis in infection due to Coxsackie virus group B, type 3. N Engl J Med. 1959;261(3):126-8. DOI:10.1056/NEJM195907162610304
13. Agranat AL. A near-fatal case of Coxsackie B1 myocarditis (with pericarditis) in an adult. S Afr Med J. 1961;35:831-3. PMID:13859634
14. Smith WG. Adult heart disease due to the Coxsackie virus group B. Br Heart J. 1966;28(2):204-20. DOI:10.1136/hrt.28.2.204
15. McDermott M, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97(1):133-44. DOI:10.1016/s0092-8674(00)80721-7
16. Bonaventura A, Vecchié A, Mauro AG, et al. An update on the pathophysiology of acute and recurrent pericarditis. Panminerva Med. 2021;63(3):249-60. DOI:10.23736/S0031-0808.20.04205-6
17. Yang X, Lin G, Han Z, Chai J. Structural Biology of NOD-Like Receptors. Adv Exp Med Biol. 2019;1172:119-41. DOI:10.1007/978-981-13-9367-9_6
18. Sundaram B, Kanneganti TD. Advances in understanding activation and function of the NLRC4 inflammasome. Int J Mol Sci. 2021;22(3):1048. DOI:10.3390/ijms22031048
19. Jiang L, Shao Y, Tian Y, et al. Nuclear alarmin cytokines in inflammation. J Immunol Res. 2020;2020:7206451. DOI:10.1155/2020/7206451
20. Vong CT, Tseng HHL, Yao P, et al. Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases. Drug Discov Today. 2021;26(6):1394-408. DOI:10.1016/j.drudis.2021.02.018
21. Tombetti E, Casarin F, Bizzi E, et al. Relapsing pericarditis: peripheral blood neutrophilia, lymphopenia and high neutrophilto-lymphocyte ratio herald acute attacks, high-grade inflammation, multiserosal involvement, and predict multiple recurrences. Int J Rheum Dis. 2023;26(2):337-43. DOI:10.1111/175 6-185X.14523
22. Imazio M, Brucato A, Maestroni S, et al. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: Implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation. 2011;123(10):1092-7. DOI:10.1161/CIRCULATIONAHA.110.986372
23. Перикардиты. Клинические рекомендации РКО 2025. Режим доступа: https://scardio.ru/content/Guidelines/KR_Perikardity.pdf. Ссылка активна на 10.11.2025 [Perikardity. Klinicheskie rekomendatsii RKO 2025. Available at: https://scardio.ru/content/Guidelines/KR_Perikardity.pdf. Accessed: 10.11.2025 (in Russian)].
24. Klein AL, Wang TKM, Cremer PC, et al. Pericardial diseases: International position statement on new concepts and advances in multimodality cardiac imaging. JACC Cardiovasc Imaging. 2024;17:937-88. DOI:10.1016/j.jcmg.2024.04.010
25. Wang TKM, Ayoub K, Chetrit M, et al. Cardiac magnetic resonance imaging techniques and their application in pericardial diseases. Circ Cardiovasc Imaging. 2022;15:e014283. DOI:10.1161/CIRCIMAGING.122.014283
26. Klein AL, Abbara S, Agler DA, et al. American Society of Echocardiography clinical practice guidelines for multimodality cardiovascular imaging in patients with pericardial disease: Endorsed by the Society of Cardiovascular Magnetic Resonance Imaging and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2013;26(9):965-1012.e15. DOI:10.1016/j.echo.2013.06.023
27. Wang TKM, Klein AL, Cremer PC, et al. 2025 Concise Clinical Guidance: An ACC Expert Consensus statement on the diagnosis and management of pericarditis: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2025;86(25):2691-719. DOI:10.1016/j.jacc.2025.05.023
28. Horneffer PJ, Miller RH, Pearson TA, et al. The effective treatment of ostpericardiotomy syndrome after cardiac operations. A randomized placebo-controlled trial. J Thorac Cardiovasc Surg. 1990;100:292-6. PMID:2200931
29. Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160(14):2093-9. DOI:10.1001/archinte.160.14.2093
30. Lamberts M, Lip GY, Hansen ML, et al. Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: A nationwide cohort study. Ann Intern Med. 2014;161(10):690-8. DOI:10.7326/M13-1581
31. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153(4):477-84. PMID:8435027
32. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S-24S. DOI:10.1016/s0002-9343(99)00113-8
33. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: A meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3(4):231-41. DOI:10.1016/S2468-1253(18)30037-2
34. Rodríguez de la Serna A, Guindo Soldevila J, Martí Claramunt V, Bayés de Luna A. Colchicine for recurrent pericarditis. Lancet. 1987;2(8574):1517. DOI:10.1016/s0140-6736(87)92641-9
35. Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. 2021;42(28):2745-60. DOI:10.1093/eurheartj/ehab221
36. Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute Pericarditis: results of the Colchicine for acute Pericarditis (COPE) trial. Circulation. 2005;112(13):2012-6. DOI:10.1161/CIRCULATIONAHA.105.542738
37. Imazio M, Brucato A, Cemin R, et al.; ICAP investigators. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522-8. DOI:10.1056/NEJMoa1208536
38. Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent Pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155(7):409-14. DOI:10.7326/0003-4819-155-7-201110040-00360
39. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of Colchicine for treatment of multiple recurrences of Pericarditis (CORP-2): A multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383(9936):2232-7. DOI:10.1016/S0140-6736(13)62709-9
40. Imazio M, Brucato A, Cumetti D, et al. Corticosteroids for recurrent pericarditis: high versus low doses: A nonrandomized observation. Circulation. 2008;118(6):667-71. DOI:10.1161/CIRCULATIONAHA.107.761064
41. Lazaros G, Antonopoulos AS, Vlachopoulos C, et al. Predictors of switching from nonsteroidal anti-inflammatory drugs to corticosteroids in patients with acute pericarditis and impact on clinical outcome. Hellenic J Cardiol. 2019;60(6):357-63. DOI:10.1016/j.hjc.2018.04.001
42. Imazio M, Lazaros G. Corticosteroids for pericarditis: A warning but don’t throw the baby out with the bathwater. Hellenic J Cardiol. 2019;60(6):364-5. DOI:10.1016/j.hjc.2019.04.002
43. Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis in patients with colchicine resistance and corticosteroid dependence: The AIRTRIP randomized clinical trial. JAMA. 2016;316(18):1906-12. DOI:10.1001/jama.2016.15826
44. Klein AL, Imazio M, Brucato A, et al. RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis. Am Heart J. 2020;228:81-90. DOI:10.1016/j.ahj.2020.07.004
45. Myachikova VY, Maslyanskiy AL, Moiseeva OM, et al. Treatment of idiopathic recurrent pericarditis with goflikicept: Phase II/III study results. J Am Coll Cardiol. 2023;82(1):30-40. DOI:10.1016/j.jacc.2023.04.046
46. Imazio M, Brucato A, Mayosi BM, et al. Medical therapy of pericardial diseases: Part II: Noninfectious pericarditis, pericardial effusion and constrictive pericarditis. J Cardiovasc Med (Hagerstown). 2010;11(11):785-94. PMID: 20925146.
47. Imazio M, Brucato A, Maestroni S, et al. Risk of constrictive pericarditis after acute pericarditis. Circulation. 2011;124(11):1270-5. DOI:10.1161/CIRCULATIONAHA.111.018580
________________________________________________
2. Skajaa N, Horváth-Puhó E, Adelborg K, et al. Lack of seasonality in occurrence of pericarditis, myocarditis, and endocarditis. Ann Epidemiol. 2019;37:77-80. DOI:10.1016/j.annepidem.2019.07.005
3. Chiabrando JG, Bonaventura A, Vecchié A, et al. Management of acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(1):76-92. DOI:10.1016/j.jacc.2019.11.021
4. Myachikova VYu, Maslyanskiy AL, Moiseeva OM. Idiopathic recurrent pericarditis – a new orphan autoinflammatory disease? A retrospective analysis of cases of idiopathic recurrent pericarditis and a design of а double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of RPH-104 treatment in patients with idiopathic recurrent pericarditis. Kardiologiia. 2021;61(1):72-7 (in Russian). DOI:10.18087/cardio.2021.1.n1475
5. Perechen' redkikh (orfannykh) zabolevanii. 2025. Available at: https://minzdrav.gov.ru/documents/9641-perechen-redkih-orfannyh-zabolevaniy. Accessed: 05.06.2025 (in Russian).
6. Arlie R, Barnes MD, Howard B, Burchell MD. Acute pericarditis simulating acute coronary occlusion: A report of fourteen cases. Am Heart J. 1942;23(2):247-68. DOI:10.1016/S0002-8703(42)90383-1
7. Wolff L. Acute pericarditis simulating myocardial infarction. New Engl J Med. 1944;230:422-5.
8. Bourne WA. Acute pericarditis simulating myocardial infarction. Br Med J. 1949;2(4627):579. DOI:10.1136/bmj.2.4627.579
9. Peel AAF. Diseases of the heart and circulation. London, New York: Geoffrey Cumberlege, Oxford University Press, 1947.
10. Cross EG, Charles WB. Idiopathic pericarditis. Can Med Assoc J. 1953;68(3):237-43. PMID:13032863
11. Dressler W. A post-myocardial infarction syndrome; preliminary report of a complication resembling idiopathic, recurrent, benign pericarditis. J Am Med Assoc. 1956;160(16):1379-83. DOI:10.1001/jama.1956.02960510005002
12. Bell JF, Meis A. Pericarditis in infection due to Coxsackie virus group B, type 3. N Engl J Med. 1959;261(3):126-8. DOI:10.1056/NEJM195907162610304
13. Agranat AL. A near-fatal case of Coxsackie B1 myocarditis (with pericarditis) in an adult. S Afr Med J. 1961;35:831-3. PMID:13859634
14. Smith WG. Adult heart disease due to the Coxsackie virus group B. Br Heart J. 1966;28(2):204-20. DOI:10.1136/hrt.28.2.204
15. McDermott M, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97(1):133-44. DOI:10.1016/s0092-8674(00)80721-7
16. Bonaventura A, Vecchié A, Mauro AG, et al. An update on the pathophysiology of acute and recurrent pericarditis. Panminerva Med. 2021;63(3):249-60. DOI:10.23736/S0031-0808.20.04205-6
17. Yang X, Lin G, Han Z, Chai J. Structural Biology of NOD-Like Receptors. Adv Exp Med Biol. 2019;1172:119-41. DOI:10.1007/978-981-13-9367-9_6
18. Sundaram B, Kanneganti TD. Advances in understanding activation and function of the NLRC4 inflammasome. Int J Mol Sci. 2021;22(3):1048. DOI:10.3390/ijms22031048
19. Jiang L, Shao Y, Tian Y, et al. Nuclear alarmin cytokines in inflammation. J Immunol Res. 2020;2020:7206451. DOI:10.1155/2020/7206451
20. Vong CT, Tseng HHL, Yao P, et al. Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases. Drug Discov Today. 2021;26(6):1394-408. DOI:10.1016/j.drudis.2021.02.018
21. Tombetti E, Casarin F, Bizzi E, et al. Relapsing pericarditis: peripheral blood neutrophilia, lymphopenia and high neutrophilto-lymphocyte ratio herald acute attacks, high-grade inflammation, multiserosal involvement, and predict multiple recurrences. Int J Rheum Dis. 2023;26(2):337-43. DOI:10.1111/175 6-185X.14523
22. Imazio M, Brucato A, Maestroni S, et al. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: Implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation. 2011;123(10):1092-7. DOI:10.1161/CIRCULATIONAHA.110.986372
23. Perikardity. Klinicheskie rekomendatsii RKO 2025. Available at: https://scardio.ru/content/Guidelines/KR_Perikardity.pdf. Accessed: 10.11.2025 (in Russian).
24. Klein AL, Wang TKM, Cremer PC, et al. Pericardial diseases: International position statement on new concepts and advances in multimodality cardiac imaging. JACC Cardiovasc Imaging. 2024;17:937-88. DOI:10.1016/j.jcmg.2024.04.010
25. Wang TKM, Ayoub K, Chetrit M, et al. Cardiac magnetic resonance imaging techniques and their application in pericardial diseases. Circ Cardiovasc Imaging. 2022;15:e014283. DOI:10.1161/CIRCIMAGING.122.014283
26. Klein AL, Abbara S, Agler DA, et al. American Society of Echocardiography clinical practice guidelines for multimodality cardiovascular imaging in patients with pericardial disease: Endorsed by the Society of Cardiovascular Magnetic Resonance Imaging and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2013;26(9):965-1012.e15. DOI:10.1016/j.echo.2013.06.023
27. Wang TKM, Klein AL, Cremer PC, et al. 2025 Concise Clinical Guidance: An ACC Expert Consensus statement on the diagnosis and management of pericarditis: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2025;86(25):2691-719. DOI:10.1016/j.jacc.2025.05.023
28. Horneffer PJ, Miller RH, Pearson TA, et al. The effective treatment of ostpericardiotomy syndrome after cardiac operations. A randomized placebo-controlled trial. J Thorac Cardiovasc Surg. 1990;100:292-6. PMID:2200931
29. Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160(14):2093-9. DOI:10.1001/archinte.160.14.2093
30. Lamberts M, Lip GY, Hansen ML, et al. Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: A nationwide cohort study. Ann Intern Med. 2014;161(10):690-8. DOI:10.7326/M13-1581
31. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153(4):477-84. PMID:8435027
32. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S-24S. DOI:10.1016/s0002-9343(99)00113-8
33. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: A meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3(4):231-41. DOI:10.1016/S2468-1253(18)30037-2
34. Rodríguez de la Serna A, Guindo Soldevila J, Martí Claramunt V, Bayés de Luna A. Colchicine for recurrent pericarditis. Lancet. 1987;2(8574):1517. DOI:10.1016/s0140-6736(87)92641-9
35. Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. 2021;42(28):2745-60. DOI:10.1093/eurheartj/ehab221
36. Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute Pericarditis: results of the Colchicine for acute Pericarditis (COPE) trial. Circulation. 2005;112(13):2012-6. DOI:10.1161/CIRCULATIONAHA.105.542738
37. Imazio M, Brucato A, Cemin R, et al.; ICAP investigators. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522-8. DOI:10.1056/NEJMoa1208536
38. Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent Pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155(7):409-14. DOI:10.7326/0003-4819-155-7-201110040-00360
39. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of Colchicine for treatment of multiple recurrences of Pericarditis (CORP-2): A multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383(9936):2232-7. DOI:10.1016/S0140-6736(13)62709-9
40. Imazio M, Brucato A, Cumetti D, et al. Corticosteroids for recurrent pericarditis: high versus low doses: A nonrandomized observation. Circulation. 2008;118(6):667-71. DOI:10.1161/CIRCULATIONAHA.107.761064
41. Lazaros G, Antonopoulos AS, Vlachopoulos C, et al. Predictors of switching from nonsteroidal anti-inflammatory drugs to corticosteroids in patients with acute pericarditis and impact on clinical outcome. Hellenic J Cardiol. 2019;60(6):357-63. DOI:10.1016/j.hjc.2018.04.001
42. Imazio M, Lazaros G. Corticosteroids for pericarditis: A warning but don’t throw the baby out with the bathwater. Hellenic J Cardiol. 2019;60(6):364-5. DOI:10.1016/j.hjc.2019.04.002
43. Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis in patients with colchicine resistance and corticosteroid dependence: The AIRTRIP randomized clinical trial. JAMA. 2016;316(18):1906-12. DOI:10.1001/jama.2016.15826
44. Klein AL, Imazio M, Brucato A, et al. RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis. Am Heart J. 2020;228:81-90. DOI:10.1016/j.ahj.2020.07.004
45. Myachikova VY, Maslyanskiy AL, Moiseeva OM, et al. Treatment of idiopathic recurrent pericarditis with goflikicept: Phase II/III study results. J Am Coll Cardiol. 2023;82(1):30-40. DOI:10.1016/j.jacc.2023.04.046
46. Imazio M, Brucato A, Mayosi BM, et al. Medical therapy of pericardial diseases: Part II: Noninfectious pericarditis, pericardial effusion and constrictive pericarditis. J Cardiovasc Med (Hagerstown). 2010;11(11):785-94. PMID: 20925146.
47. Imazio M, Brucato A, Maestroni S, et al. Risk of constrictive pericarditis after acute pericarditis. Circulation. 2011;124(11):1270-5. DOI:10.1161/CIRCULATIONAHA.111.018580
Авторы
А.А. Сафиуллина1, А.А. Петрухина*1, Ю.Ф. Осмоловская1, И.В. Жиров1,2, С.Н. Терещенко1,2
1ФГБУ «Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова» Минздрава России, Москва, Россия;
2ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия
*angelina-heart@yandex.ru
1Chazov National Medical Research Center of Cardiology, Moscow, Russia;
2Russian Medical Academy of Continuous Professional Education, Moscow, Russia
*angelina-heart@yandex.ru
1ФГБУ «Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова» Минздрава России, Москва, Россия;
2ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия
*angelina-heart@yandex.ru
________________________________________________
1Chazov National Medical Research Center of Cardiology, Moscow, Russia;
2Russian Medical Academy of Continuous Professional Education, Moscow, Russia
*angelina-heart@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.